RHINEBECK, N.Y., July 7 KD-Pharma, the fully-owned subsidiary of the specialty pharmaceutical company Bioseutica, can produce what it claims to be the market's safest and highest quality Omega-3 concentrations.
KD-Pharma designed, developed and patented the kd-pur manufacturing process which can produce specific, customized combinations of Omega-3 EPA/DHA at concentrations of up to 99 percent.
KD-Pharma's CEO, Rudi Krumbholz claims that "kd-pur produces a safer and more effective product because it reduces to a minimum the production of trans fatty acids and the oxidation of PUFAs (polyunsaturated fatty acids), especially in the peroxide form, which are known to cause cancer."
This can be achieved by the implementation of advanced super critical fluid technology, conducted under mild temperatures, generally below 45 Celsius and under CO2 atmospheric conditions to extract, refine and concentrate highly purified Omega-3s from fish oil.
The process can also remove other undesired components from Omega-3s such as Omega-6, saturated fats, cholesterol and contaminants. This means that every dose of kd-pur Omega-3 products has less interference from undesired components, which would translate into better metabolic and therapeutic activity, and a better safety profile.
Unlike other manufacturing processes, such as short way distillation and liquid chromatography, the kd-pur process uses no organic solvents or isomers.
"Most competitors using other technologies can produce concentrations up to 70 percent. And the handful of companies able to produce concentrations of EPA and DHA over 70 percent utilize more standards technologies which are not as environmentally friendly (as kd-pur) and as efficient in eliminating unwanted components and contaminants," Krumbholz added.
Varying the ratio of EPA and DHA allows the company to target specific health conditions including cardiovascular, brain function and the anti-inflammatory category.
"A composition richer in EPA, for instance, is known to have a greater activity on cardiovascular health or depression while a composition with a greater amount of DHA would be more beneficial in supporting eye health or treating dementia," said Krumbholz.
Bioseutica CEO, Stefano Ferrari claims that "While higher concentration Omega-3s may seem to be more expensive than Omega-3 products with lower (mostly 30 percent) concentration found at most retail stores, the reality is that the less expensive Omega-3 supplements have a greater cost on health."
"In a 1gm soft gel a 90 percent formulation would contain 900mg of Omega-3 and 100mg of other components while a 30 percent formulation would contain 300mg of Omega-3 and 700mg of other nonessential components," Mr. Ferrari said. "Consequently, to take the same amount of Omega-3 as in a 90 percent product one would have to take three 30 percent capsules as opposed to one 90 percent capsule. With the 30 percent concentration you are ingesting an additional 700mg of non essential and perhaps harmful components."
CONTACT: Andre Doren, of Bioseutica, +1-845-876-8616, [email protected]